Eeva – Embryo development time-lapse imaging
What is Eeva™?
The Early Embryo Viability Assessment (Eeva) test is the first and only non-invasive IVF test clinically proven to increase the accuracy of predicting viable embryos at an early stage. The Eeva test was developed based on landmark research conducted at Stanford University, in the United States, which discovered that early cell division timings are an accurate predictor of viability and underlying health of the embryo.
At the heart of Eeva is intelligent software that reliably and consistently assesses critical and subtle differences in early embryo development, with the help of time-lapse photography. This data helps embryologists and IVF clinicians determine an embryo’s viability, and to select the embryos with the highest potential for transfer or freezing. Eeva is designed to safely identify which embryos are most likely to develop to blastocyst stage – a critical stage in embryo development that typically happens on ‘day’ 5 or 6. With access to this unique information, your IVF team can more accurately select the best embryo(s) for transfer, and this could improve your chances for a successful pregnancy.
What are the benefits of Eeva to patients?
There are many factors that contribute to a successful live birth, but identifying viable embryos in the first few days is one of the most critical. The benefits of Eeva include:
- Improved ability in selecting the most viable embryos. Since its introduction in October 2012 through to May 2015 we have had over 500 IVF/ ICSI treatment cycles in patients who have elected to use Eeva.
- Objective information early in the process allows embryologists to make informed decisions regarding which embryos to transfer or freeze
- Increased consistency amongst embryologists
Who is Eeva suitable for?
Whether you are on your first IVF cycle or second, Eeva is suitable for all patients undergoing IVF treatment. By providing access to critical and subtle differences in the early stages of embryo development, Eeva provides embryologists and consultants with objective information about the underlying health of the embryo. This information is critical in making informed decisions about your treatment path.
How do I learn more about Eeva?
GCRM is proud to be among the first clinics in the world to offer this new test.
***First baby born in Scotland using new ground-breaking IVF technology***
Baby Eva named after the test that gave her life
We are delighted to announce the birth of the first baby to be born in Scotland using the ground-breaking new approach to IVF, the ‘Early Embryo Viability Assessment’ (Eeva) test, that improves embryo selection. The Eeva test uses unique predictive software in combination with a time-lapse analysis technique to automatically analyse embryo development against scientifically and clinically validated cell-division parameters. The test aids embryologist in selecting the most viable embryos for transfer, potentially increasing the chances of a successful IVF cycle.
Professor Richard Fleming (Scientific Director at GCRM) said: “We are very proud to be among the first clinics in the world to announce this news as it demonstrated how successful this new technology can be in enabling couples to have a higher chance of conceiving a baby with IVF. GCRM has always strived to be one of the leading IVF Centres in Europe, offering couples the latest innovations with the best possible outcomes. The Eeva test is the practical end point of good quality research and is thr start of a new chapter in the evolution of IVF”.
“We are delighted to hear the news of this successful birth and wish the family the very best. “ said Lissa Goldenstein, president and CEO of Auxogyn Inc “The Eeva test has been developed to give IVF clinicians objective information about the embryo and provide insight into its growth potential. With more couples choosing to use Eeva, we are looking forward to many more births like Baby Eva today.”